Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, Bart Ghesquière et al.|Annals of Neurology|2021Cited by 57
Neurodevelopmental and Epilepsy Phenotypes in Individuals With Missense Variants in the Voltage-Sensing and Pore Domains of <i>KCNH5</i>Hannah C. Happ, Elizabeth E. Gerard, Roseline Caumes et al.|Neurology|2022Cited by 23
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohortChristina Lam, Roni Zemet, Audrey Squire et al.|Molecular Genetics and Metabolism|2024Cited by 19
Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directionsKarthik Muthusamy, Éva Morava, Christin Johnsen et al.|Genetics in Medicine|2023Cited by 17
eP028: Neurological manifestations in PMM2 related congenital disorders of glycosylation (CDG): Insights into clinico-radiological characteristics and recommendations for follow-upKarthik Muthusamy, Eva Morava‐Kozicz, Suzanne Boyer et al.|Genetics in Medicine|2022Cited by 0